Citi Upgrades Prime Medicine (PRME) to Buy

May 16, 2024 5:10 AM EDT Send to a Friend
Citi analyst Samantha Semenkow upgraded Prime Medicine (NASDAQ: PRME) from Neutral to Buy with a price target of $10.00.The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login